Infection prophylaxis and antiretroviral therapy in patients with HIV infection and malignancy

Joseph A. Sparano, Catherine Sarta

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Systemic non-Hodgkin's lymphoma and Kaposi's sarcoma occur in approximately 4% and 30% of patients with HIV infection, respectively. Single-agent or combination chemotherapy is often indicated for such patients. Combination chemotherapy produces a significant decrease in CD4 lymphocytes and significantly increases the risk of opportunistic infection. Supportive care should include prophylaxis against Pneumocystis carinii pneumonia and esophageal candidiasis. Herpes labialis frequently occurs, may be confused with chemotherapy-induced stomatitis, and it requires appropriate treatment and secondary prophylaxis once recognized. Antiretroviral therapy should be continued during chemotherapy, if possible, and should be selected based on the patient's prior antiretroviral exposure, the toxicity profile of the antiretroviral agent, the toxicity of the chemotherapy, and the potential for drug interaction. The use of hematopoietic growth factors as primary prophylaxis may be reasonable for patients at high risk for febrile neutropenia, although the information about their use in this population is limited.

Original languageEnglish (US)
Pages (from-to)392-399
Number of pages8
JournalCurrent Opinion in Oncology
Volume8
Issue number5
StatePublished - 1996

Fingerprint

HIV Infections
Infection
Combination Drug Therapy
Drug Therapy
Neoplasms
Herpes Labialis
Anti-Retroviral Agents
Febrile Neutropenia
Stomatitis
Pneumocystis Pneumonia
Candidiasis
Kaposi's Sarcoma
Opportunistic Infections
Therapeutics
Drug Interactions
Non-Hodgkin's Lymphoma
Intercellular Signaling Peptides and Proteins
Lymphocytes
Population

ASJC Scopus subject areas

  • Cancer Research

Cite this

Infection prophylaxis and antiretroviral therapy in patients with HIV infection and malignancy. / Sparano, Joseph A.; Sarta, Catherine.

In: Current Opinion in Oncology, Vol. 8, No. 5, 1996, p. 392-399.

Research output: Contribution to journalArticle

@article{60797e273978438a91dfe2cd8263f89b,
title = "Infection prophylaxis and antiretroviral therapy in patients with HIV infection and malignancy",
abstract = "Systemic non-Hodgkin's lymphoma and Kaposi's sarcoma occur in approximately 4{\%} and 30{\%} of patients with HIV infection, respectively. Single-agent or combination chemotherapy is often indicated for such patients. Combination chemotherapy produces a significant decrease in CD4 lymphocytes and significantly increases the risk of opportunistic infection. Supportive care should include prophylaxis against Pneumocystis carinii pneumonia and esophageal candidiasis. Herpes labialis frequently occurs, may be confused with chemotherapy-induced stomatitis, and it requires appropriate treatment and secondary prophylaxis once recognized. Antiretroviral therapy should be continued during chemotherapy, if possible, and should be selected based on the patient's prior antiretroviral exposure, the toxicity profile of the antiretroviral agent, the toxicity of the chemotherapy, and the potential for drug interaction. The use of hematopoietic growth factors as primary prophylaxis may be reasonable for patients at high risk for febrile neutropenia, although the information about their use in this population is limited.",
author = "Sparano, {Joseph A.} and Catherine Sarta",
year = "1996",
language = "English (US)",
volume = "8",
pages = "392--399",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Infection prophylaxis and antiretroviral therapy in patients with HIV infection and malignancy

AU - Sparano, Joseph A.

AU - Sarta, Catherine

PY - 1996

Y1 - 1996

N2 - Systemic non-Hodgkin's lymphoma and Kaposi's sarcoma occur in approximately 4% and 30% of patients with HIV infection, respectively. Single-agent or combination chemotherapy is often indicated for such patients. Combination chemotherapy produces a significant decrease in CD4 lymphocytes and significantly increases the risk of opportunistic infection. Supportive care should include prophylaxis against Pneumocystis carinii pneumonia and esophageal candidiasis. Herpes labialis frequently occurs, may be confused with chemotherapy-induced stomatitis, and it requires appropriate treatment and secondary prophylaxis once recognized. Antiretroviral therapy should be continued during chemotherapy, if possible, and should be selected based on the patient's prior antiretroviral exposure, the toxicity profile of the antiretroviral agent, the toxicity of the chemotherapy, and the potential for drug interaction. The use of hematopoietic growth factors as primary prophylaxis may be reasonable for patients at high risk for febrile neutropenia, although the information about their use in this population is limited.

AB - Systemic non-Hodgkin's lymphoma and Kaposi's sarcoma occur in approximately 4% and 30% of patients with HIV infection, respectively. Single-agent or combination chemotherapy is often indicated for such patients. Combination chemotherapy produces a significant decrease in CD4 lymphocytes and significantly increases the risk of opportunistic infection. Supportive care should include prophylaxis against Pneumocystis carinii pneumonia and esophageal candidiasis. Herpes labialis frequently occurs, may be confused with chemotherapy-induced stomatitis, and it requires appropriate treatment and secondary prophylaxis once recognized. Antiretroviral therapy should be continued during chemotherapy, if possible, and should be selected based on the patient's prior antiretroviral exposure, the toxicity profile of the antiretroviral agent, the toxicity of the chemotherapy, and the potential for drug interaction. The use of hematopoietic growth factors as primary prophylaxis may be reasonable for patients at high risk for febrile neutropenia, although the information about their use in this population is limited.

UR - http://www.scopus.com/inward/record.url?scp=0029909611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029909611&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 392

EP - 399

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 5

ER -